Author
B. Parekkadan
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
Biology Disciplines
Click to filter author papersSignature Assays, Organisms & Methods
Click to filter · or open tagActivity by Year
2020-2023 · peak 2/yrCo-Author Collaboration Network
10 top collaborators · 18 mutual co-author links4 papers
Recent·Most cited
3D Microcapsules for Human Bone Marrow Derived Mesenchymal Stem Cell Biomanufacturing in a Vertical-Wheel Bioreactor
M. Teryek, P. Jadhav, R. Bento, B. Parekkadan
This study develops a method to expand human mesenchymal stem cells in microcapsules using electrospraying and a vertical-wheel bioreactor, achieving 10x expansion while preserving cell quality and enabling genetic modification.
bioRxiv · Feb 16, 2023Bioengineering
Neutralizing IFNL3 Autoantibodies in Severe COVID-19 Identified Using Molecular Indexing of Proteins by Self-Assembly
J. J. Credle, J. Gunn, P. Sangkhapreecha, D. R. Monaco, X. A. Zheng, H.-J. Tsai, A. Wilbon, W. R. Morgenlander, Y. Dong, S. Jayaraman, L. Tosi, B. Parekkadan, A. N. Baer, M. Roederer, E. M. Bloch, , H. B. Larman
MIPSA identifies neutralizing IFNL3 autoantibodies in severe COVID-19 patients by profiling autoantibodies against DNA-barcoded proteins.
bioRxiv · Mar 2, 2021 · PreprintImmunology
Mesenchymal Stromal Cell Delivery via an Ex Vivo Bioreactor Preclinical Test System Attenuates Clot Formation for Intravascular Application
B. O'Rourke, S. Nguyen, A. Tilles, J. Bynum, A. Cap, B. Parekkadan, R. Barcia
This study shows that using a bioreactor to isolate mesenchymal stromal cells (MSCs) delays clot formation compared to free MSCs, suggesting improved safety for systemic administration.
bioRxiv · Nov 20, 2020Bioengineering